Inhibikase Therapeutics, Inc. (IKT) stock
IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$1.38+0.00 (0.00%)
Close on Nov 18, 2026Market cap $192.56MP/E –Yield –
Inhibikase Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Inhibikase Therapeutics's total debt was $0 at Dec 31, 2025. For fiscal 2025 it was $0, down 100.0% from the year before. The highest annual figure on record is $276.46K in fiscal 2020.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $110.52K | -26.4% |
| FY2023 | Dec 31, 2023 | $150.10K | +2.9% |
| FY2022 | Dec 31, 2022 | $145.84K | – |
| FY2021 | Dec 31, 2021 | $0 | -100.0% |
| FY2020 | Dec 31, 2020 | $276.46K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0 | -100.0% |
| Q2 FY2025 | Jun 30, 2025 | $37.94K | -75.1% |
| Q1 FY2025 | Mar 31, 2025 | $74.77K | -50.5% |
| Q4 FY2024 | Dec 31, 2024 | $110.52K | -26.4% |
| Q3 FY2024 | Sep 30, 2024 | $145.21K | -2.6% |
| Q2 FY2024 | Jun 30, 2024 | $152.22K | +2.9% |
| Q1 FY2024 | Mar 31, 2024 | $151.16K | +2.9% |
| Q4 FY2023 | Dec 31, 2023 | $150.10K | +2.9% |
| Q3 FY2023 | Sep 30, 2023 | $149.03K | +4.9% |
| Q2 FY2023 | Jun 30, 2023 | $147.97K | – |
| Q1 FY2023 | Mar 31, 2023 | $146.90K | -41.0% |
| Q4 FY2022 | Dec 31, 2022 | $145.84K | -41.4% |
| Q3 FY2022 | Sep 30, 2022 | $142.05K | -48.6% |
| Q4 FY2021 | Dec 31, 2021 | $0 | – |
| Q2 FY2021 | Jun 30, 2021 | $248.91K | – |
| Q1 FY2021 | Mar 31, 2021 | $248.91K | – |
| Q4 FY2020 | Dec 31, 2020 | $276.46K | – |
See a number that looks wrong?